Jazz Pharmaceuticals plc completed its acquisition of Actio Biosciences, Inc., a Delaware corporation, for an upfront payment of $820 million on September 15, 2026. Following the transaction, Actio became a wholly-owned subsidiary of Jazz. The acquisition adds ABS-1230, a clinical-stage potential first-in-class precision therapy targeting KCNT1-related epilepsy, to Jazz's pipeline. ABS-1230 is an orally available small molecule KCNT1 inhibitor that has received Fast Track, Rare Pediatric Disease, and Orphan Drug Product designations from the U.S. FDA. Actio spun out non-ABS-1230 programs into a new private entity funded by existing investors, with Jazz retaining a minority stake. Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing life-changing medicines for patients with rare diseases.

Jazz Pharmaceuticals plc completed a private offering of $1.25 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032, including the full exercise of the initial purchasers' option to purchase an additional $150 million. Net proceeds are estimated at approximately $1,226.4 million for general corporate purposes. Concurrently, the company repurchased approximately $225.0 million of its ordinary shares from note purchasers at a price of $249.29 per share using existing cash on hand, reducing the remaining authorization under its July 2024 buyback program. The notes mature on September 15, 2032, with semi-annual interest payments beginning March 15, 2027, and an initial exchange rate of 2.8150 ordinary shares per $1,000 principal amount. Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing treatments for rare diseases.

On August 25, 2026, the U.S. Food and Drug Administration approved two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma. The approvals cover Ziihera combined with Tevimbra (tislelizumab-jsgr) and chemotherapy for all HER2+ patients, as well as Ziihera plus chemotherapy for HER2+ IHC 3+ patients. This approval is based on the Phase 3 HERIZON-GEA-01 trial, which reported a median overall survival of 26.4 months versus 19.2 months for the control arm. Jazz Pharmaceuticals plc operates in the biopharmaceutical industry, developing and commercializing medicines for rare diseases, including cancers and sleep disorders.

On August 10, 2026, Jazz Pharmaceuticals plc announced it has entered into a definitive Agreement and Plan of Merger to acquire Actio Biosciences, Inc. The transaction values the acquisition at an initial Aggregate Upfront Transaction Value of $820 million, adjusted for cash, indebtedness, and transaction expenses. Shareholders will receive this value on a fully diluted per-share basis. Additionally, holders are entitled to contingent milestone payments totaling up to $500 million, including a $250 million development milestone upon regulatory approval for ABS-1230 for KCNT1-Related Epilepsy, and sales milestones of $100 million and $150 million at $500 million and $1 billion in annual net sales, respectively. The deal requires the completion of a spin-out transaction separating non-ABS-1230 programs into a new entity called SpinCo, where Jazz will hold a minority stake. Closing is subject to customary conditions, including HSR Act clearance and 85% stockholder approval from Actio Biosciences. Jazz Pharmaceuticals plc operates in the biopharmaceutical industry, focusing on the development and commercialization of medicines for serious neurological disorders.

Jazz Pharmaceuticals plc announced a definitive agreement to acquire privately-held Actio Biosciences for an $820 million upfront payment and up to $500 million in contingent consideration. The transaction adds ABS-1230, a clinical-stage KCNT1 inhibitor for rare epilepsy, to Jazz's portfolio. The deal is expected to close by the fourth quarter of 2026, subject to customary conditions. This acquisition expands Jazz Pharmaceuticals' leadership in rare and severe epilepsies.

Jazz Pharmaceuticals plc reported second quarter 2026 financial results on August 3, 2026, announcing record total revenues of $1.2 billion, a 16% increase year-over-year. The company raised its full-year 2026 revenue guidance to $4.60–$4.75 billion from the previous range of $4.25–$4.50 billion. Key product performance included Xywav net sales of $471 million (up 13%) with 525 new patients, Epidiolex/Epidyolex sales of $292 million (up 16%), and Zepzelca sales of $106 million (up 42%). The firm generated $824 million in cash from operations during the first half of 2026 and repaid $1.0 billion in senior notes in June. Jazz Pharmaceuticals is a global biopharmaceutical company focused on developing therapies for rare diseases, including sleep disorders, epilepsy, and cancer.